Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the
treatment of a variety of human diseases. Recent advances in develo** clinically …

Adeno-associated virus (AAV) has emerged as a leading platform for gene delivery for
treating various diseases due to its excellent safety profile and efficient transduction to …

Transfection is a powerful analytical tool enabling studies of gene products and functions in
eukaryotic cells. Successful delivery of genetic material into cells depends on DNA quantity …

There has been a resurgence in gene therapy efforts that is partly fueled by the identification
and understanding of new gene delivery vectors. Adeno-associated virus (AAV) is a non …

In the past decade, recombinant vectors based on a non-pathogenic parvovirus, the adeno-
associated virus (AAV), have taken center stage as a gene delivery vehicle for the potential …

Gene therapy has emerged as a promising therapeutic strategy for various conditions,
including blood disorders, ocular disease, cancer, and nervous system disorders. The …

Recombinant adeno-associated viral (rAAV) vectors have been used in more than 150
clinical trials with a good safety profile and significant clinical benefit in many genetic …

Currently, there are over 150 ongoing clinical trials utilizing adeno-associated viruses
(AAVs) to target various genetic diseases, including hemophilia (AAV2 and AAV8) …

Over the last two decades, gene therapy vectors based on wild‐type Adeno‐associated
viruses (AAV) are safe and efficacious in numerous clinical trials and are translated into …

Adeno-associated viruses (AAVs) are useful vehicles for gene therapy because of their
stability, low immunogenicity. and non-pathogenicity. However, disparity in AAV sample …